Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins

Read full text Summarise with VIRAT
Authors: Muhammad Salah ud din, Muhammad Adnan, Ihtisham Saeed, Abidullah, Nazeef Ullah, Noor Faraz
Cited by: 0
References: 12

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Dyslipidaemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a leading modifiable risk factor for cardiovascular disease (CVD), which accounts for approximately 30–40% of adult mortality in Pakistan. Despite statin availability, LDL-C target attainment remains poor in high-risk Pakistani patients, necessitating evaluation of combination lipid-lowering strategies. Objective: To compare the efficacy and safety of rosuvastatin monotherapy versus rosuvastatin-ezetimibe combination therapy in reducing LDL-C among high-risk cardiovascular patients at a tertiary care centre in Peshawar, Pakistan. Methods: A retrospective cohort study was conducted between June 2022 and June 2023 (n = 150; 75 per arm). Adults aged 30–75 years with hypercholesterolaemia (LDL-C ≥100 mg/dL) and established CVD risk factors were included. Fasting lipid profiles were recorded at baseline and at 12 weeks. The primary outcome was absolute and proportional LDL-C reduction; secondary outcomes included changes in total cholesterol, triglycerides, HDL-C, and apolipoprotein B (ApoB). Between-group comparisons were performed using independent-samples t-tests, with Bonferroni correction applied for secondary outcomes. Results: Baseline LDL-C was comparable between groups (144.12 ± 26.12 vs 142.46 ± 24.98 mg/dL; p = 0.681). At 12 weeks, LDL-C decreased to 91.60 ± 28.90 mg/dL in the rosuvastatin arm (36.5% reduction) and to 88.75 ± 29.73 mg/dL in the combination arm (37.7% reduction); the between-group difference was 2.85 mg/dL (95% CI: 0.39–5.31; p = 0.0234). Neither group achieved the guideline LDL-C target of

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Blood Pressure and Hypertension Studies Cancer Lipids and Metabolism

Publication details

Journal / source
Journal of Health Wellness and Community Research
Pages
e1375–e1375
Publication date
15 January 2026
Language
EN